Studies using the proteasome inhibitor (MG132) or the IKKβ inhibitor (AS602868) demonstrated that the pharmacological targeting of NF-κB induced cell death in AML cells both in vitro and in vivo, without affecting normal bone marrow CD34+CD38− cells [78,80,81]. Here, NFKB1 is linked to acute myeloid leukemia.